Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 2/20 | 0.39 |
| ▸ | FEN1 | P39748 | 2/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.37 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL981337 | 0.95 | CHEK1 (0.44) | CHEK1ACKR3FNTAFNTBCHEK2 | |
| SCHEMBL13615327 | 0.94 | ACKR3 (0.41) | CHEK1ACKR3FNTAFNTBCHEK2 | |
| SCHEMBL982318 | 0.91 | CHEK1 (0.46) | CHEK1FNTAFNTBCHEK2CNR1 | |
| SCHEMBL4342898 | 0.90 | ACKR3 (0.42) | CHEK1ACKR3FNTAFNTBCHEK2 | |
| SCHEMBL1496097 | 0.89 | ACKR3 (0.46) | CHEK1ACKR3FNTAFNTBCHEK2 | |
| SCHEMBL13615283 | 0.85 | ALDH1A1 (0.43) | ACKR3FNTAFNTBCNR1CNR2 | |
| SCHEMBL12948547 | 0.85 | CHEK1 (0.51) | CHEK1 | |
| SCHEMBL4355506 | 0.84 | ACKR3 (0.40) | ACKR3FNTAFNTBCHEK2CNR1 | |
| SCHEMBL982003 | 0.84 | CHEK1 (0.46) | CHEK1CHEK2FEN1ALOX5AP | |
| SCHEMBL13085848 | 0.83 | CHEK1 (0.50) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962626-B2 | Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2015-02-24 | — | — | US | disclosed |
| US-8318740-B2 | Compounds for protein kinase inhibition | WU ZHANGGUI (US) | 2012-11-27 | — | — | US | disclosed |
| CN-101481380-B | Thiofuran pyridazine compound, preparation thereof, pharmaceutical composition and uses thereof | ZHEJIANG MED XINCHANG PHARM | 2012-10-17 | — | — | CN | disclosed |
| EP-2241569-B1 | THIENOPYRIDAZINE COMPOUNDS, THEIR PREPARATIONS, PHARMACEUTICAL COMPOSITIONS AND USES | ZHEJIANG MED XINCHANG PHARM (CN) | 2012-05-23 | — | — | EP | disclosed |
| US-20110009415-A1 | Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses | WU, ZHANGGUI (CN) | 2011-01-13 | — | — | US | disclosed |
| EP-2241569-A1 | THIENOPYRIDAZINE COMPOUNDS, THEIR PREPARATIONS, PHARMACEUTICAL COMPOSITIONS AND USES | Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory (CN) | 2010-10-20 | — | — | EP | disclosed |
| US-20090275585-A1 | Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition | WU ZHANGGUI | 2009-11-05 | — | — | US | disclosed |
| CN-101481380-A | Thiofuran pyridazine compound, preparation thereof, pharmaceutical composition and uses thereof | ZHEJIANG MEDICINE CO LTD (CN) | 2009-07-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009415-A1 | Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses | CYP3A5, ABCC5, DPYD | CHEK1 2344/4885ACKR3 950/4885FNTA 1645/4885 |
| US-20090275585-A1 | Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition | CHEK2, CHEK1, PLK1 | CHEK1 2/4885ACKR3 3285/4885FNTA 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.